Compare IART & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IART | FTRE |
|---|---|---|
| Founded | 1989 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.5B |
| IPO Year | 1995 | N/A |
| Metric | IART | FTRE |
|---|---|---|
| Price | $13.60 | $17.38 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 9 |
| Target Price | $15.00 | ★ $15.56 |
| AVG Volume (30 Days) | 774.3K | ★ 1.3M |
| Earning Date | 02-24-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,642,966,000.00 | ★ $2,759,900,000.00 |
| Revenue This Year | $3.26 | $3.17 |
| Revenue Next Year | $2.71 | $0.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.99 | 1.88 |
| 52 Week Low | $10.87 | $3.97 |
| 52 Week High | $27.13 | $19.53 |
| Indicator | IART | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 60.39 | 66.77 |
| Support Level | $11.86 | $16.91 |
| Resistance Level | $14.12 | $18.26 |
| Average True Range (ATR) | 0.54 | 0.89 |
| MACD | 0.12 | -0.18 |
| Stochastic Oscillator | 81.85 | 56.62 |
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.